PMV Pharmaceuticals IncPMVP
Price$1.75

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$75.2MTTM through 30 Jun 2026
Free Cash Flow -$71.3MTTM through 30 Jun 2026

Margins

Current
Gross Margin0.0%

Returns

-74.3%ROE
-66.7%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio10.09x
Net Debt-$112.9Mnet cash position
Cash & Equivalents$12.5M

Quality Metrics

Altman Z-Score-5.82
Piotroski F-Score1 / 9
Earnings-Beat Rate75.0%

Multi-Year Trend

Diluted EPS-$1.42TTM
'20'21'22'23'24'25
FY2025: $-1.48

Dividend

No dividend

Capital Allocation

R&D Spend$64M

Segment Performance

SegmentRevenueYoYOutlook
Precision Oncology$00.0%
View details

NDA submission for platinum-resistant/refractory ovarian cancer patients with TP53 Y220C mutation planned for Q1 2027.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.